What it is
Cetrorelix is a GnRH antagonist — a ten-amino-acid copy of the brain hormone GnRH, altered so that it blocks the hormone's receptor. The Cetrotide label describes it as "a synthetic decapeptide with gonadotropin-releasing hormone (GnRH) antagonistic activity," with substitutions at positions 1, 2, 3, 6 and 10:
| Position | Natural GnRH | Cetrorelix (label) |
|---|---|---|
| 1 | pyroglutamate | Ac-D-Nal (acetyl-D-3-(2'-naphthyl)alanine) |
| 2 | His | D-Cpa (D-4-chlorophenylalanine) |
| 3 | Trp | D-Pal (D-3-(3'-pyridyl)alanine) |
| 4–5 | Ser-Tyr | Ser-Tyr |
| 6 | Gly | D-Cit (D-citrulline) |
| 7–9 | Leu-Arg-Pro | Leu-Arg-Pro |
| 10 | Gly-NH2 | D-Ala-NH2 |
Five of the ten are D-amino acids, the mirror-image forms, and four (naphthylalanine, chlorophenylalanine, pyridylalanine, citrulline) are not among the twenty amino acids that make up ordinary proteins. The natural column is gonadorelin, pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2 (PubChem synonym); the library's gonadorelin entry covers it. The label gives a molecular weight of 1,431.06; PubChem records C70H92ClN17O14 (CID 25074887).
How it works
GnRH from the hypothalamus tells the pituitary to release LH and FSH. In the middle of a natural cycle, rising oestradiol boosts GnRH and produces the LH surge that releases the egg. In IVF, several follicles are grown with injected FSH, and an early surge would release the eggs before they can be collected.
Cetrorelix competes with natural GnRH for its receptor on pituitary cells (label). The label reports:
| Property | Figure (label) |
|---|---|
| Start of LH suppression | about 2 h after 0.25 mg (about 1 h after 3 mg) |
| Initial hormone flare | none detected |
| Effect on LH v FSH | more pronounced on LH |
| Bioavailability under the skin | 85% |
| Half-life, one 0.25 mg dose | 5.0 h (range 2.4–48.8) |
| Half-life, 14 daily doses | 20.6 h (range 4.1–179.3) |
| Reversible on stopping | yes |
That absence of a flare is the practical difference from the GnRH agonists such as leuprolide and goserelin, which first stimulate the receptor before suppressing it. Degarelix is another antagonist, used in prostate cancer.
What the evidence shows
The label's dosing describes the standard schedule: FSH or hMG from cycle day 2 or 3, then cetrorelix 0.25 mg under the skin once daily from stimulation day 5 or 6, continued until the day of the hCG trigger. It is reported here as the label's wording, not as a protocol.
The safety set is 949 women aged 19 to 40 (mean 32) given doses from 0.1 to 5 mg:
| Event | Rate |
|---|---|
| Ovarian hyperstimulation syndrome, moderate or severe | 3.5% (33) |
| Nausea | 1.3% (12) |
| Headache | 1.1% (10) |
Injection-site reactions were short-lived and mild. After marketing, mild to moderate OHSS and hypersensitivity, including anaphylactoid reactions, have been reported. The label also records two stillbirths in the phase 3 studies and, in a follow-up of 316 newborns, one twin born with anencephaly.
ClinicalTrials.gov lists 143 studies naming cetrorelix, most of them comparing IVF stimulation protocols in which it is one component. A separate line, cetrorelix pamoate intramuscular injections for benign prostatic hyperplasia, reached two phase 3 trials by AEterna Zentaris (NCT00670306, 528 participants; NCT00663858, 420), completed in 2009 and 2010 with results posted. This entry did not open their comparative results, and the US label carries no prostate indication.
Where it stands
Cetrotide was approved in the US on 11 August 2000 (NDA 021197, EMD Serono), for the inhibition of premature LH surges in women undergoing controlled ovarian stimulation — its only indication. Drugs@FDA lists generic cetrorelix acetate from Qilu, Livzon and Gland, approved between 16 and 25 April 2024. It is a prescription medicine used under a fertility specialist; the library's ganirelix entry covers the other GnRH antagonist with the same use, and hCG the trigger it is paired with.
Sources opened 2026-11-18: Cetrotide label (openFDA, effective 2025-09-22: indications, dosage, description, clinical pharmacology, pharmacokinetics, adverse reactions); Drugs@FDA NDA 021197 and ANDAs 214540, 217776, 218150; PubChem CID 25074887 and the gonadorelin record's synonyms; ClinicalTrials.gov API v2 (143 records; NCT00670306 and NCT00663858 records and results flags); PubMed E-utilities counts.
